Pro Health Fitness


BREAKING: AI Blood Test May Detect Silent Killer – Ovarian Cancer!

AI Blood Test May Detect Silent Killer - Ovarian Cancer

United States: Using AI to track fragments of tumor-associated DNA in the blood, scientists say they may be close to an accurate test for a silent killer: Ovary cancer.

This is the fifth most common cause of death from cancer disease in America. Ovarian tumors that typically make no noticeable symptoms can make effective treatment quite difficult for the patients.

Dr. Victor Velculescu, the senior study author and co-director of the Cancer Genetics and Epigenetics Program at the Johns Hopkins Kimmel Cancer Center in Baltimore, said, “Ovarian cancer is an incredibly deadly disease with no great biomarkers for screening and early intervention,” as US News reported.

His team made a presentation of its research results on Tuesday during the scientific conference AACR, held in San Diego.

An increasingly precise liquid biopsy blood test capable of detecting cancer cells of ovarian tumors has been the focus of chemists for a long time.

The experiment laid the emphasis precisely on short pieces of DNA extracted from patients’ blood that are a part of the tumor’s genetic structure.

The study co-first author Jamie Medina, a postdoctoral fellow at Kimmel, said, “Because cancer cells are rapidly growing and dying and have chaotic genomes as compared to healthy cells, patients with cancer have different patterns of DNA fragments in their blood than patients without cancer.”

“By carefully analyzing these fragments across the entire human genome, we can detect subtle patterns indicating the presence of cancer,” Medina added.

They made use of the artificial intelligence program, which was in charge of the analysis of the DNA blood “fragmentomes” of women with and without ovarian cancer. The AI program was merged into the data with the results of blood levels of CA125 and HE4, which are two ovarian cancer biomarkers.

Moreover, as Velculescu said, the team hoped this mix could produce “a new high-performance approach for early detection of ovarian cancer.”

More about the study

Visual Representation of ovarian cancer. Credit | iStock

In this case, 134 women with ovarian cancer and, 204 women without cancer, 203 women with benign adnexal (ovarian) masses were in the study group.

The results were impressive: The assay had a specificity of 99 percent, which means that there were practically see very few women who received false-positive results after testing.

During the study of the particular test, its sensitivity actually depended on the cancer stage. To illustrate, it managed to identify cancer in stage 1 with a 69 percent success rate; in stage 2, it managed to produce a prognosis with 76 percent probability; stage 3 yielded a success rate of 85 percent; and stage 4 had a perfect score of 100 percent.

Leave a Reply

Your email address will not be published. Required fields are marked *